W.H.O. confirms that cheap steroids reduce Covid deaths 36%, page-26

Well, absolutely. But that's the point — the staff are interested in the most clinically competitive therapy, which is still being shaken out. The steroid studies confirm a significant competitor, perhaps expanding/consolidating that treatment choice. This is worth examining from an investment point of view.

Which is the reason this platform exists.

And keeping in mind that competition is frequently hostile, if competitors can derail the adoption of cellular therapies they will. I want this option in ICU. That's another reason for keeping all risks on our radar.